IP4 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Innocan Pharma Corp

Watchlist Manager

Watchlist

Price: 10.6 EUR -5.36% Market Closed

Market Cap: €2.8B

I	Innocan Pharma Corp DUS:IP4	IL
A	Amadeus IT Group SA XMUN:AI3A	ES
B	Barrick Gold Corp F:ABR	CA

Profitability Summary

Innocan Pharma Corp's profitability score is 40/100. We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

90%

Strong 3Y Average Gross Margin

90%

Gross Margin is Increasing

89% > 90%

Negative Operating Margin

-5%

Negative 3Y Average Operating Margin

-27%

Operating Margin is Increasing

-148% > -5%

Negative Net Margin

-4%

Negative 3Y Average Net Margin

-28%

Net Margin is Increasing

-114% > -4%

Healthy Free Cash Flow Margin

Negative 3Y Average Free Cash Flow Margin

-27%

Free Cash Flow Margin is Increasing

-148% > 2%

Negative ROE

-21%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-82%

ROIC is Increasing

-317% > 131%

View All

Hide

Collapse

40 / 100

Profitability
Score

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

90%

Strong 3Y Average Gross Margin

90%

Gross Margin is Increasing

89% > 90%

Negative Operating Margin

-5%

Negative 3Y Average Operating Margin

-27%

Operating Margin is Increasing

-148% > -5%